# DESCRIPTION

## FIELD OF THE INVENTION

- relate to cancer field

## BACKGROUND OF THE INVENTION

- introduce thyroid cancer
- describe limitations of current diagnosis
- motivate need for new diagnostic tools

## SUMMARY OF THE INVENTION

- introduce improved diagnostic panel
- describe panel composition
- outline method for distinguishing benign and malignant tumors
- describe application to special high-risk populations
- outline specific embodiments of the method
- describe performance characteristics of the method
- outline treatment options for malignant tumors

## DETAILED DESCRIPTION OF THE INVENTION

- define scope and terminology
- describe background and prior art
- introduce invention and its embodiments

### I. Definitions

- define "about"
- explain ranges
- define "alteration"
- define "control"
- define "detect"
- define "nucleotide sequence"
- explain complementarity
- define "gene"
- define "gene expression"
- define "gene product"
- define "coding sequence"
- define "isolated" or "purified" nucleic acid
- define "antibody"
- define biomarker
- define level of biomarker
- define indicator
- define label
- define primer, probe, and oligonucleotide
- define nucleic acid probe
- define primer
- define immobilized
- define solid support
- define diagnosis
- define treating
- define therapeutically effective amount
- define positive response
- define prognosis
- define classifying a thyroid lesion
- define agent
- define optional
- disclaimer on definitions

### II. Sample Preparation for Detection of Expression

- process sample prior to detection
- extract and isolate nucleic acid and/or proteins
- remove contaminants and assay inhibitors
- add biomarker capture reagent
- incubate and separate target biomarker: capture reagent complex

### III. Detection of Target Nucleic Acid

- amplify biomarker nucleic acid
- measure levels of biomarker nucleic acid expression
- use reverse transcription and PCR
- design primers for amplification
- use multiplex qRT-PCR
- combine reverse transcription and PCR
- use labeled probes and/or primers for detection
- detect amplified or unamplified biomarker nucleic acid
- use different probes or primers with distinguishable labels
- attach label to probe or primer
- use direct or indirect detection methods
- detect biomarker nucleic acid by direct binding
- use indirect detection methods with biotinylated probe
- use fluorescent reporter dyes as labels
- use hybridization-stabilizing moieties

### IV. Detection of Target Protein(s)

- introduce immunoassay
- describe traditional immunoassays
- explain SELDI-based immunoassay
- quantify expression levels by immunoassay
- describe binding agents and detection agents
- introduce aptamers as alternative binding agents
- describe multiplex assays
- explain solid phase substrates and carriers
- introduce electrochemiluminescent assay
- describe other detection methods
- introduce biochips and protein biochips
- describe microarray chip

### V. Treatment of Patients Guided by Target Biomarker Panel

- introduce treatment modality for thyroid cancer
- describe thyroid surgical procedures
- specify TERT inhibitor treatment
- list TERT modulator antagonists
- specify BRAF inhibitor treatment
- list BRAF inhibitors
- specify MEK inhibitor treatment
- list MEK inhibitors
- describe external beam radiation therapy
- list thyroid hormone therapy
- list anti-cancer drugs
- provide examples of anti-cancer drugs
- conclude treatment options

### VI. Kits for Detection of Target Biomarkers

- define kit composition
- describe kit components
- specify kit instructions
- outline immunoassay kit embodiments
- outline nucleic acid-based detection kit embodiments
- describe PCR kit embodiments
- summarize kit usage and applications

## EXAMPLES

- provide complete disclosure of invention
- illustrate accuracy of process conditions

### Materials and Methods

- collect clinical samples
- isolate RNA and synthesize cDNA
- perform PCR and qPCR
- analyze data

### Results

- select candidate gene isoforms
- validate isoforms on FNA samples
- analyze expression profiles
- evaluate diagnostic performance

### Discussion

- introduce molecular testing for thyroid tumors
- discuss limitations of current tests
- describe development of new molecular test
- highlight importance of NIFTP diagnosis
- discuss study limitations and future directions

### Conclusions

- summarize development of 5-transcript model for thyroid nodule diagnosis

## Example 2: Assays for Sample Preparation and Detection of 5 Biomarkers and 1 Load-Control Marker.

- describe sample preparation and detection of biomarkers

### Regions for the Primer Design:

- list primer design regions for 6 genes

### Example 3: Development of a High Sensitivity and Specificity Test to Evaluate Preoperative Thyroid Fine Needle Aspiration Cytology Material.

- introduce goal of developing high sensitivity and specificity test
- describe initial gene expression signature development
- explore splice variants of original 12 gene set
- develop quantitative real-time PCR versions for candidate transcripts
- address issues with clinical FNA samples
- test approach on cohort of archival and freshly collected FNA samples
- summarize results and improved assay sensitivity and specificity

